Moderna, Inc. Accounts Receivable, Allowance for Credit Loss
Moderna, Inc. (MRNA) had Accounts Receivable, Allowance for Credit Loss of $6.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-07-31
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss $6.00M.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss $6.00M.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $3.00M.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss $3.00M.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $6.00M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $6.00M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $3.00M 10-Q · filed 2026-07-31 |
| 2025-09-30 | $3.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $12.00M 10-Q · filed 2025-08-01 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |